BetterLife Pharma (BETRF) Convertible Debt (2013 - 2022)

BetterLife Pharma (BETRF) posted quarterly Convertible Debt of $210786.0 for Q3 2022, up 4.99% quarter-over-quarter from $200766.5 in Q2 2022.

BetterLife Pharma (BETRF) Convertible Debt (2013 - 2022) Analysis & Trends

BetterLife Pharma's Convertible Debt history runs 6 years deep, the most recent figure standing at $210786.0 for Q3 2022.

In Q3 2022, Convertible Debt changed N/A year-over-year to $210786.0; the TTM figure through Jul 2022 stood at $210786.0 (changed N/A YoY), while the FY2022 annual figure was $189927.1, changed N/A from the prior year.
Convertible Debt for Q3 2022 stood at $210786.0, up from $200766.5 in the prior quarter.
The five-year high for Convertible Debt was $3.5 million in Q3 2018, with the low at $187944.6 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.60 Bn	130.75 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.93 Bn	77.93 Bn	3.93 Bn
3	Argenx Se	65.06 Bn	59.88 Bn	1.37 Bn
4	Moderna	56.22 Bn	51.08 Bn	52.00 Mn
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.65 Bn	28.34 Bn	992.69 Mn
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.48 Bn	-
10	BetterLife Pharma	33.62 Mn	33.60 Mn	-

Download Data